Compare Abeona Therapeutics Inc (ABEO) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs NICE Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while NICE Ltd trades at $96.76 (market cap $5.88B). The key difference: NICE Ltd is far larger — about 15.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | NICE | |
|---|---|---|
Market Cap | $373.32M | $5.88B |
Sector | Health | Technology |
52-Week High | $7.23 | $171.98 |
52-Week Low | $4.17 | $83.15 |
Enterprise Value | $228.22M | $5.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NICE trades at $97.17, up 0.44% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong profitability with a 65.79% gross margin and 17.57% net income margin, while recent news highlights AI platform expansions with Sopra Steria and AWS European Sovereign Cloud deployment (Business Wire, 2026-07-01).
The stock presents a compelling value opportunity with a P/E of 11.53 below sector averages, supported by a $124.88 analyst price target implying 28% upside. Risks include projected net income decline to $530M in 2026 and overbought short-term RSI levels. Wall Street sentiment remains positive with 13 buy ratings and no sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
